Cargando…

Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release

Introduction: Multiple myeloma (MM) is characterized by a high prevalence of thrombotic complications. Microvesicles (MVs) are small membrane vesicles released from activated cells, and they may potentially contribute to thrombosis. Methods: We have evaluated the plasma levels of MVs and cytokines (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gidaro, Antonio, Manetti, Roberto, Delitala, Alessandro Palmerio, Soloski, Mark Johns, Lambertenghi Deliliers, Giorgio, Castro, Dante, Soldini, Davide, Castelli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143530/
https://www.ncbi.nlm.nih.gov/pubmed/35628848
http://dx.doi.org/10.3390/jcm11102720
_version_ 1784715828834336768
author Gidaro, Antonio
Manetti, Roberto
Delitala, Alessandro Palmerio
Soloski, Mark Johns
Lambertenghi Deliliers, Giorgio
Castro, Dante
Soldini, Davide
Castelli, Roberto
author_facet Gidaro, Antonio
Manetti, Roberto
Delitala, Alessandro Palmerio
Soloski, Mark Johns
Lambertenghi Deliliers, Giorgio
Castro, Dante
Soldini, Davide
Castelli, Roberto
author_sort Gidaro, Antonio
collection PubMed
description Introduction: Multiple myeloma (MM) is characterized by a high prevalence of thrombotic complications. Microvesicles (MVs) are small membrane vesicles released from activated cells, and they may potentially contribute to thrombosis. Methods: We have evaluated the plasma levels of MVs and cytokines (IL-10, IL-17, and TGF-β in MM and Watch and Wait Smoldering MM (WWSMM) from patients and related them to thrombotic complications. The secondary aim was to assess the impact of ongoing therapy on MV and on cytokine levels. Result: 92 MM and 31 WWSMM were enrolled, and 14 (12%) experienced a thrombotic episode. Using univariate analysis, TGF-β and MV were significantly higher in patients with thrombotic events (p = 0.012; p = 0.008, respectively). Utilizing a Cox proportional hazard model, we confirmed this difference (TGF-β p = 0.003; Odds ratio 0.001, 95% CI 0–0.003 and MV p = 0.001; Odds ratio 0.003, 95% CI 0.001–0.005). Active treatment management displayed higher levels of MV (p < 0.001) and lower levels of glomerular filtration-rate (p < 0.001), IL-17 (p < 0.001) as compared to the WWSMM group. The TGF-β values of immunomodulatory derivatives patients were lower in the WWSMM (p < 0.001) and Dexamethasone/Bortezomib subgroup (p < 0.001). Conclusion: The increased levels of MVs in active regimens add insight into the mechanisms of hypercoagulation in MM. In addition, a role for cytokine-related thrombosis is also suggested.
format Online
Article
Text
id pubmed-9143530
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91435302022-05-29 Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release Gidaro, Antonio Manetti, Roberto Delitala, Alessandro Palmerio Soloski, Mark Johns Lambertenghi Deliliers, Giorgio Castro, Dante Soldini, Davide Castelli, Roberto J Clin Med Article Introduction: Multiple myeloma (MM) is characterized by a high prevalence of thrombotic complications. Microvesicles (MVs) are small membrane vesicles released from activated cells, and they may potentially contribute to thrombosis. Methods: We have evaluated the plasma levels of MVs and cytokines (IL-10, IL-17, and TGF-β in MM and Watch and Wait Smoldering MM (WWSMM) from patients and related them to thrombotic complications. The secondary aim was to assess the impact of ongoing therapy on MV and on cytokine levels. Result: 92 MM and 31 WWSMM were enrolled, and 14 (12%) experienced a thrombotic episode. Using univariate analysis, TGF-β and MV were significantly higher in patients with thrombotic events (p = 0.012; p = 0.008, respectively). Utilizing a Cox proportional hazard model, we confirmed this difference (TGF-β p = 0.003; Odds ratio 0.001, 95% CI 0–0.003 and MV p = 0.001; Odds ratio 0.003, 95% CI 0.001–0.005). Active treatment management displayed higher levels of MV (p < 0.001) and lower levels of glomerular filtration-rate (p < 0.001), IL-17 (p < 0.001) as compared to the WWSMM group. The TGF-β values of immunomodulatory derivatives patients were lower in the WWSMM (p < 0.001) and Dexamethasone/Bortezomib subgroup (p < 0.001). Conclusion: The increased levels of MVs in active regimens add insight into the mechanisms of hypercoagulation in MM. In addition, a role for cytokine-related thrombosis is also suggested. MDPI 2022-05-11 /pmc/articles/PMC9143530/ /pubmed/35628848 http://dx.doi.org/10.3390/jcm11102720 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gidaro, Antonio
Manetti, Roberto
Delitala, Alessandro Palmerio
Soloski, Mark Johns
Lambertenghi Deliliers, Giorgio
Castro, Dante
Soldini, Davide
Castelli, Roberto
Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title_full Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title_fullStr Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title_full_unstemmed Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title_short Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
title_sort incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143530/
https://www.ncbi.nlm.nih.gov/pubmed/35628848
http://dx.doi.org/10.3390/jcm11102720
work_keys_str_mv AT gidaroantonio incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT manettiroberto incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT delitalaalessandropalmerio incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT soloskimarkjohns incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT lambertenghideliliersgiorgio incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT castrodante incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT soldinidavide incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease
AT castelliroberto incidenceofvenousthromboembolisminmultiplemyelomapatientsacrossdifferentregimensroleofprocoagulantmicroparticlesandcytokinerelease